Johnson & Johnson Q2 FY26 EPS slips 0.9% to $2.27; net sales rise 6.6% to $25.31 billion - JNJ News | RalliesJohnson & Johnson Q2 FY26 EPS slips 0.9% to $2.27; net sales rise 6.6% to $25.31 billion
J
JNJ• Johnson & Johnson reports Q2 2026 results and raises outlook
- Johnson & Johnson posted Q2 2026 net sales of $25.31 billion, up 6.6% year over year.
- Net earnings edged down 0.1% to $5.53 billion, while diluted EPS slipped 0.9% to $2.27.
- Innovative Medicine net sales climbed 7.8% to $16.38 billion, while MedTech rose 4.5% to $8.93 billion.
- Free cash flow was about $8.7 billion, up from $6.21 billion a year earlier.
- The company raised its 2026 outlook, projecting reported sales of $100.8 billion to $101.4 billion.
•
